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Canine idiopathic pulmonary fibrosis (CIPF) affects old dogs from the West Highland white
terrier (WHWT) breed and mimics idiopathic pulmonary fibrosis (IPF) in human. The
disease results from deposition of fibrotic tissue in the lung parenchyma causing
respiratory failure. Recent studies in IPF using single-cell RNA sequencing (scRNA-seq)
revealed the presence of profibrotic macrophage populations in the lung, which could be
targeted for therapeutic purpose. In dogs, scRNA-seq was recently validated for the
detection of cell populations in bronchoalveolar lavage fluid (BALF) from healthy dogs.
Here we used the scRNA-seq to characterize disease-related heterogeneity within cell
populations of macrophages/monocytes (Ma/Mo) in the BALF from five WHWTs affected
with CIPF in comparison with three healthy WHWTs. Gene set enrichment analysis was
also used to assess pro-fibrotic capacities of Ma/Mo populations. Five clusters of Ma/Mo
were identified. Gene set enrichment analyses revealed the presence of pro-fibrotic
monocytes in higher proportion in CIPF WHWTs than in healthy WHWTs. In addition,
monocyte-derived macrophages enriched in pro-fibrotic genes in CIPF compared with
healthy WHWTs were also identified. These results suggest the implication of Ma/Mo
clusters in CIPF processes, although, further research is needed to understand their role in
disease pathogenesis. Overexpressed molecules associated with pulmonary fibrosis
processes were also identified that could be used as biomarkers and/or therapeutic
targets in the future.
Keywords: macrophages, canine idiopathic pulmonary fibrosis, dog, single-cell RNA-sequencing methods,
bronchoalveolar lavage fluid, lungorg December 2020 | Volume 11 | Article 6117491
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Canine idiopathic pulmonary fibrosis (CIPF) is defined as a
progressive and abnormal accumulation of collagen in the lung
parenchyma that threatens alveolar gas exchange and reduces
lung compliance causing cough, exercise intolerance, and, finally,
respiratory failure and death (1, 2). The disease affects
predominantly middle-aged to old dogs from the West
Highland white terrier (WHWT) breed (1, 2). Although the
cause of CIPF is not identified, a genetic etiology is suspected as it
affects mainly one breed. Confirmation of the diagnostic remains
challenging due to absence of available diagnostic biomarkers
and necessity to exclude other diseases and comorbidities. It
currently relies on either thoracic high-resolution computed
tomography (HRCT) or histopathology of the lung tissue or
both. Despite a lot of researches on CIPF, the pathophysiology
remains unclear and no curative treatment are available (1, 2).
CIPF shares several clinical findings with human idiopathic
pulmonary fibrosis (IPF). However, thoracic HRCT and
histopathology show features associated with both human IPF
and non-specific interstitial pneumonia demonstrating that CIPF
and IPF are not strictly identical (1, 2). In spite of those
differences, studying CIPF in WHWTs is worth to better
understand IPF. Indeed, dogs, like human, are subjected to
various environmental stresses which can have an impact on
lung cells especially alveolar macrophages (AMs) (3). Moreover,
CIPF is a disease that develops spontaneously in WHWTs (1, 2).
Those characteristics make the dog a much more interesting
model compared to the mouse experimental models. In human
IPF and IPF mouse models, recent studies used single-cell
mRNA sequencing (scRNA-seq) to detect altered cell
populations compared with healthy conditions through an
unbiased approach (4–13). Indeed, the technique allows high-
throughput and high-resolution analysis of thousands of cells at
the same time without requiring prior knowledge of cell markers
to determine cell heterogeneity (14–16). With this method, a
profibrotic role of specific macrophage and monocyte
populations has been described in IPF patients and IPF mouse
models (4, 6, 7, 12, 17). An increased number of macrophages
and proliferating myeloid cells was found in bleomycin-induced
lung fibrosis mouse models, in the beginning of lung fibrosis
development, before fibroblastic infiltration (6). Specific
monocyte and macrophage clusters were identified in fibrosis
conditions (4, 5, 7, 12). AMs from IPF patients were enriched in
functions involved in fibrotic processes including “extra-cellular
matrix organization” and “regulation of cell migration” for
example (5). Pro-fibrotic macrophage but also monocyteAbbreviations: CIPF, Canine idiopathic pulmonary fibrosis; WHWT, West
Highland white terrier; HRCT, High-resolution computed tomography; IPF,
Idiopathic pulmonary fibrosis; ScRNA-seq, Single-cell RNA sequencing; AMs,
Alveolar macrophages; BALF, Bronchoalveolar lavage fluid; Ma/Mo,
Macrophages/monocytes; DC, Dendritic cell; 6MWD, 6-min walked distance;
TCC, Total cell count; DCC, Differential cell count; GSEA, Gene set enrichment
analysis; FDR, False discovery rate; GO, Gene ontology; DEG, Differentially
expressed gene; Avg_log FC, Average log2 fold change; t-SNE, t-distributed
stochastic neighbor embedding; NES, Normalized enrichment score; EMT,
Epithelial mesenchymal transition; VEGF, Vascular endothelial growth factor.
Frontiers in Immunology | www.frontiersin.org 2clusters that expressed genes able to drive fibroblasts’
proliferation were localized in areas of fibrosis (4, 12). All these
findings indicate that targeting specific macrophage and
monocyte clusters could be potentially useful for the
prevention and the therapy of lung fibrosis (17).
Recently, cells of the bronchoalveolar lavage fluid (BALF) of
healthy dogs have been characterized by scRNA-seq, providing a
comprehensive single-cell expression profiling of the canine
BALF cells in healthy conditions (18). Fourteen distinct cell
populations were identified including AMs (three clusters),
macrophages/monocytes (Ma/Mo) (one cluster), CD8+ T cells,
CD8−CD4− T cells, B cells, neutrophils, mature and immature
dendritic cells (DCs), ciliated and non-ciliated epithelial cells,
mast cells, and cells in division (18).
The objective of this study was to characterize, using scRNA-
seq, disease-related heterogeneity within Ma/Mo populations in
the BALF from WHWTs affected with CIPF compared with
healthy WHWTs.MATERIALS AND METHODS
Dog Population
The scRNA-seq analysis was performed on BALF obtained from
WHWTs affected with CIPF and healthy WHWTs. Dogs were
prospectively recruited between March and October 2018 at the
veterinary clinic of the University of Liège (Liège, Belgium)
according to a protocol approved by the ethical committee of
the University of Liège (approval no. 1435). All dogs were
privately owned, and samples were obtained with owners’
written consent.
The healthy or CIPF status of the dogs was confirmed
according to a previously described approach (19) based on
history, physical examination, complete blood work, 6-min
walked distance (6MWD), thoracic HRCT, bronchoscopy, and
analysis of the BALF (including macroscopic evaluation and total
(TCC) and differential (DCC) cell count). WHWTs under
treatment including antimicrobials drugs and corticoids were
excluded from the study.
BALF Collection
BALF was obtained using the same protocol as previously
described (18). Briefly, under general anesthesia, a
bronchoscope (FUJINON© Paediatric Video-Bronchoscope
EB-530S) was inserted into the lower airways of the dogs.
Three to 4 ml/kg of sterile saline solution was instilled in the
airways through the bronchoscope channel and directly
reaspirated. A part of the crude BALF was used for TCC and
DCC obtained using respectively a hemocytometer and a
cytospin preparation. The rest of the collected fluid was then
directly transferred on ice to the GIGA laboratory of cellular and
molecular immunology (Liège, Belgium).
Single-Cell RNA Sequencing
ScRNA-seq was performed as already described (18, 20). Briefly,
BALFs were processed to obtain a final cell suspension
containing between 500 and 1,000 cells/µl suspended inDecember 2020 | Volume 11 | Article 611749
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Cat.14190-169) containing 0.04% (w/v) bovine serum albumin.
Cell viability assessed by Trypan blue staining was considered as
acceptable above 80%. Details about BALF volume, final cell
concentration and cell viability for each sample can be found in
Supplementary Table 1.
For each sample, approximatively 3,500 cells (Supplementary
Table 1) were loaded into the ChromiumTM Controller (10x
Genomics, Pleasanton, CA, USA) and were then partitioned into
nanoliter scale vesicles containing 10x barcoded beads from
ChromiumTM Single Cell 3’ Gel Bead kit v2 (10x Genomics,
Pleasanton, CA, USA) according to manufacturer’s instructions.
Reverse transcription of mRNAs took place into vesicles on a
Veriti© 96-Well Thermal Cycler (ThermoFisher Scientific,
Merelbeke, Belgium) after cell lysis and capture of
polyadenylated mRNAs.
Emulsion breakage, cDNA amplification, and libraries
construction were performed using ChromiumTM Single Cell
3′ Reagent kit v2 (10x Genomics, Pleasanton, CA, USA)
according to manufacturer’s instructions as already described
(18, 20). Libraries were assessed for quality (2100 Bioanalyser
Instrument; Agilent, Santa Clara, CA, USA) and then sequenced
on a NextSeq500 instrument (Illumina, San Diego, CA, USA).
Initial data pre-processing was performed using the Cell
Ranger software (v1.2.0) (10x Genomics, Pleasanton, CA,
USA). Reads were mapped to dog genome (CanFam3.1,
GenBank assembly accession: GCA_000002285.2). The genes
not well annotated were further blasted on the Ensembl
genome browser (v99.31) (21) for dog species.
Further data analyses were performed using R package Seurat
(version 3.1.2) (22) after the selection of the cells with a
minimum of 100 and a maximum of 2,500 unique genes
mapped, the selection of the genes found in at least three
different cells and the normalization of the expression values to
10,000 transcripts per cell. ScRNA-seq data coming from each
dog were then merged for the next analyses which were done by
following Stuart et al. (2019) instructions (22). Pre-ranked gene
set enrichment analyses (GSEAs) were performed using GSEA-P
software (v4.0.3) (23). The enrichment score was determined
using weighted Kolmogorov–Smirnov-like statistic with falseFrontiers in Immunology | www.frontiersin.org 3discovery rate (FDR) correction for multiple testing (23). A
FDR cutoff of 25%> was considered as appropriate (23).
GSEAs were computed between either the Gene Ontology
(GO) Biological Process gene sets (v7.1) (23), or the Hallmark
gene sets (v7.1) (23) or the Comparative Toxicogenomics
Database Pulmonary fibrosis gene set (24). Differentially
expressed genes (DEGs) in different conditions were obtained
using the “FindMarkers” command in Seurat (22). Differential
gene expressions were measured using non-parametric Wilcoxon
rank sum tests adjusted for multiple testing with Bonferroni
correction. Only DEGs with an average log2 fold change
(avg_logFC) >0.25 and an adjusted P-value <0.05 were retained.
Statistical Analyses
A P-value lower than 0.05 was considered as significant. Details
about statistical analyses for scRNA-seq data and GSEAs can be
found in the section above. Statistics used for the comparison of
the WHWTs groups are reported in Tables 1, 3, and 4.RESULTS
Study Population
BALF samples were obtained from three healthy WHWTs and
five WHWTs affected with CIPF. Characteristics of the dogs
included in the study are reported in Table 1. No significant
differences in age, gender, and weight were reported between the
groups (Table 1).
CIPF diagnosis was confirmed in all CIPF WHWTs by
thoracic HRCT which revealed extensive ground-glass opacity
in all dogs. Other HRCT findings included a combination of
mosaic pattern, bronchial wall thickening, parenchymal and
subpleural bands, bronchomalacia and bronchiectasis. Among
WHWTs affected with CIPF, 3/5 (60%) had an history of both
exercise intolerance and cough and 2/5 (40%) only exhibited
exercise intolerance. Crackles were heard on lung auscultation in
all dogs. Three dogs (60%) had a restrictive dyspnea. Among
them, two also exhibited cyanosis. The 6MWD covered by each
dog was in favor of exercise intolerance in all CIPF dogs.TABLE 1 | Characteristics of the West Highland white terriers either healthy or affected with canine idiopathic pulmonary fibrosis included in the study.
Healthy WHWTs (n = 3) WHWTs affected with CIPF (n = 5) P-value
Age, y 8.2 (5.4–8.7) 10.8 (10.2–12.7) 0.14a
Gender, M/F 2/1 1/4 0.46b
Weight, kg 8.4 (8.4–8.9) 9.5 (9.1–9.9) 0.14a
6MWD, m 506.1 (478.8–513.0) 356.4 (356.1–366.3) 0.04a
BALF analysis TCC, cells/µl 760 (665–770) 2,620 (2,500–3,285) 0.04a
Macrophages, % 78 (76.5–84.5) 71 (64–82) 0.39a
Neutrophils, % 3 (2.5–3.5) 10 (9–21) 0.04a
Lymphocytes, % 11 (7–16) 7 (7–16) 0.93a
Eosinophils, % 1 (1–4) 2 (1–2) 0.93a
Mast cells, % 0 0 /
Epithelial cells, % 1 (0.5–1.5) 1 (0–1) 0.46aDecember 2020 | Volume 11 | ArticleContinuous data are not normally distributed according to the Shapiro-Wilk test and are then expressed in median and interquartile range. Groups were compared using either Mann-
Whitney tests (a) or Chi-squared tests (b). WHWTs, West Highland white terriers; CIPF, canine idiopathic pulmonary fibrosis; M, male; F, female; 6MWD, 6-min walked distance; BALF,
bronchoalveolar lavage fluid; TCC, total cell count.611749
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compared with healthy WHWTs (Table 1). At echocardiography,
signs of secondary pulmonary arterial hypertension were present in
all CIPF dogs. Changes in BALF cells analysis were consistent with
non-specific chronic lung inflammation (Table 1).
Among control WHWTs included in the study, all were
clinically healthy and did not have any signs or findings
indicating pulmonary disease. Echocardiography excluded the
presence of cardiac disease in all of them. Thoracic HRCT did
not reveal significant abnormalities. BALF cells analysis was
unremarkable (Table 1).ScRNA-Seq Identifies Multiple Cell
Populations in the Dog BALF
Droplet-based scRNA-seq analysis of BALF cells was performed
with a median read depth of ∼43,000 reads per cell. In total,
19,255 cells (6,703 from healthy and 12,552 from diseased dogs)
coding for 11,722 unique genes were included in the final
analysis. The median detected genes per cell was 788
(interquartile range 399–1,191 genes/cells, Table 2). Individual
metrics about mapping and cells are displayed in Table 2, the
individual distribution for transcripts and genes counts is
illustrated in Supplementary Figures 1A and B, respectively.
Cells from all samples were combined and aligned to account
for sample variations among dogs using Seurat package in R
(version 3.1.2) (22). They were then clustered and visualized
using t-distributed stochastic neighbor embedding (t-SNE) plot
with a resolution set at 0.3 and a number of dimensions to use set
to 30 which resulted in the identification of 14 clusters (Figure
1A). After clustering, DEGs between each identified cluster were
used to assign cell types to each cluster using previously
established markers (18). Cells populations found accordingly
included Ma/Mo (5 clusters), CD8+ and CD8−CD4− T cells,
mature and immature DCs, neutrophils, B cells, epithelial cells,
mast cells and cycling cells (Figure 1B). DEGs detected in eachFrontiers in Immunology | www.frontiersin.org 4cluster are provided in Supplementary Table 2. Principal
markers used to identify cell populations can be found in
Figure 1D. Each cell population included cells coming from
healthy and diseased dogs (Figure 1C and Table 3). No
significant differences were reported in relative proportions of
the different cell types between healthy WHWTs and WHWTs
affected with CIPF, except for mature DCs (Table 3).
ScRNA-Seq Analysis Reveals Fibrosis-
Associated Transcriptomic Changes in
Ma/Mo Clusters
Comparison Between Ma/Mo Clusters
After Ma/Mo isolation from other cell populations, we
repeated clustering on those cells to better characterize changes
associated with CIPF. It resulted in the identification of five
transcriptionally distinct Ma/Mo clusters (M0, M1, M2, M3, and
M4) (Figure 2A). Average expression of all the genes expressed
by each Ma/Mo cluster can be found in Supplementary Table 3.
Relative contributions of each Ma/Mo cluster into each group of
dogs either healthy or diseased are displayed in Figures 2B, C.
Cells repartition between healthy and diseased WHWTs was
similar into each cluster except in the cluster M2 which
contained more cells in WHWTs affected with CIPF (Figures
2B, C and Table 4). We then estimated differential genes
expression between each cluster of Ma/Mo and performed
GSEAs to better characterize Ma/Mo clusters independently of
the disease status of the dogs. All DEGs identified in each cluster
compared to others are displayed in Supplementary Table 4.
Results of the enrichment analyses performed by mapping DEGs
identified in each cluster compared to others, to Hallmark gene
sets or GO Biological Process gene sets are provided in
Supplementary Table 5.
Resident AMs were identified based on MARCO expression
(Figure 3), a class A scavenger receptor (5, 12, 18, 25, 26) and
corresponded to cells in clusters M0 and M3 (Figure 2A,
Supplementary Tables 3 and 4). They represented theTABLE 2 | Metrics about mapping and characteristics of the detected cells in each bronchoalveolar lavage fluid specimen.
Sample
ID

























Healthy 1,298 59.8 23.9 834 (376–1,046) 1,889 (678–
2,671)
10,839
CIPF 1 CIPF 2,551 69.2 24.6 1,147 (827–1,346) 2,934 (1,857–
3,740)
12,988
CIPF 2 CIPF 2,686 67.3 23.4 618 (219–1,226) 1,362 (354–
3,390)
12,478
CIPF 3 CIPF 2,564 74.8 30.4 503 (355–969) 960 (601–2,247) 11,819
CIPF 4 CIPF 2,556 71.5 28.1 867 (411–1,090) 1,939 (708–
2,754)
11,722
CIPF 5 CIPF 2,195 73.1 27.5 453 (383–722) 833 (656–1,622) 11,921December 2020 | Volume 11Data were generated after passing quality control including the exclusion of cells with <100 and >2,500 genes. Only genes present in more than three cells were kept. Reads mapped
confidently to genome are the number of reads that mapped only to the genome. Reads mapped confidently to transcriptome are the fraction of the reads mapped to a unique gene in the
transcriptome and are considered for UMI counting. Median genes per cell correspond to the median number of genes with at least one UMI count. Total genes detected is the detected
number of genes with at least one UMI count in any cell. ID, identity; UMI, unique molecular identifier; WHWT, West Highland white terrier; CIPF, canine idiopathic pulmonary fibrosis.| Article 611749
s (BALFs). The scRNA-seq analysis was performed on a single-cell suspension
th canine idiopathic pulmonary fibrosis (CIPF). Cells were visualized using t-distributed
according to the status of dogs either healthy or affected with CIPF. (D) Expression of
RC1, macrophage mannose receptor; MARCO, macrophage receptor with collagenous
in; CD8b, T-cell surface glycoprotein CD8 beta chain; CCR7, C-C chemokine receptor











































FIGURE 1 | Single-cell RNA sequencing analysis identifies multiple cell populations in the canine bronchoalveolar lavage fluid
generated from eight BALFs obtained from three healthy West Highland white terriers (WHWTs) and five WHWTs affected wi
stochastic neighbor embedding (t-SNE) plots. (A) Cell clusters identified. (B) Cell populations identified. (C) Cells are colored
differentially expressed genes representative of each cell population. Ma/Mo, macrophages/monocytes; DC, dendritic cell; M
structure; CD163, scavenger receptor cysteine-rich type 1 protein M130; CD3E, T-cell surface glycoprotein CD3 epsilon cha
type 7; CD83, CD83 molecule; SELL, selectin; TOP2A, DNA topoisomerase II alpha; FCRLA, Fc receptor like A; KRT19, cyto
Fastrès et al. Pro-Fibrotic Macrophages in CIPF WHWTsmajority of the cells composing Ma/Mo population (Figures 2A,
C and Table 4). Cells in these clusters were enriched in biological
processes relevant to AMs including “Hallmark reactive oxygen
species pathways” for M0 cells and “GO adaptative immune
response,” “GO antigen processing and presentation of peptide
or polysaccharide antigen via MHC class II,” “GO activation and
regulation of immune response,” and “GO pattern recognition
receptor signaling pathway” for M3 cells (Supplementary Table
5). Cells in cluster M1 were considered as monocyte-derived
macrophages as they expressed markers from both macrophages,
including MARCO, PPARG (encoding peroxisome proliferator
activated receptor gamma), CD68,MRC1 (encoding macrophage
mannose receptor, CD206), MSR1 (encoding macrophage
scavenger receptor 1, CD204) and CD16 (5, 27–31), and
monocytes, including CD11c (encoding integrin subunit alpha
X, ITGAX), CD16, CD49d (encoding integrin subunit alpha 4,
ITGA4), CD49e (encoding integrin subunit alpha 5, ITGA5) and
CX3CR1 (encoding fractalkine receptor) (Figure 3 ,
Supplementary Tables 3 and 4) (29, 30, 32, 33). A cluster of
monocytes which corresponded to cluster M2 was also identified.
Indeed, M2 cells expressed only monocytes markers (Figure 3)
including CSF2RB (encoding colony stimulating factor 2Frontiers in Immunology | www.frontiersin.org 6receptor subunit beta, CD131), CD11c, CD11b (encoding
integrin subunit alpha M, ITGAM), CD49d, CD49e, and
CX3CR1 (Figure 3, Supplementary Tables 3 and 4) (29, 30,
32–34). Cells in cluster M1 were enriched in functions associated
with the immune response activation including “Hallmark
inflammatory response,” “GO interferon gamma production,”
and “GO leukocyte cell-cell adhesion,” while cells in cluster M2
were more involved in “GO leukocyte migration” and “GO cell
motility” (Supplementary Table 5), functions essential when
monocytes are recruited from blood into tissues. M4 cells also
expressed macrophages and monocytes markers including
notably MHC-II markers, CD63, CD68, CD16, and CD49d (12,
30, 32, 33, 35), but they also overexpressed CD3 genes compared
with other clusters (Figure 3 and Supplementary Tables 3 and
4) which are known to be T-lymphocyte markers (36). Enriched
processes associated with M4 cluster were mainly focused on
inflammatory response (Supplementary Table 5).
For each cluster independently of the animal status (healthy or
affected with CIPF), we also performed a GSEA to determine
whether overexpressed genes in each cluster, in comparison with
other clusters, could be associated with signatures of pulmonary
fibrosis using the Comparative Toxicogenomics Database
Pulmonary fibrosis gene set (24). Only cells in cluster M1 and
M2 showed significant enrichment for pulmonary fibrosis with aA B C
FIGURE 2 | Macrophages/monocytes (Ma/Mo) clusters identified. Cells identified as Ma/Mo after the annotation of scRNA-Seq data obtained from three healthy
West Highland white terriers (WHWTs) and five WHWTs affected with canine idiopathic pulmonary fibrosis (CIPF) were selected and then clustered allowing the
identification of five distinct clusters. (A) Clusters identified. Cells were visualized using a t-distributed stochastic neighbor embedding (t-SNE) plot. (B) t-SNE plot of
Ma/Mo colored according to the disease status of the WHWTs either healthy or affected with CIPF. (C) Bar plot of the relative proportion in each disease status of
each Ma/Mo cluster.TABLE 3 | Relative cells repartition between healthy and CIPF WHWTs in each
cell population.
Healthy WHWTs CIPF WHWTs P-value
Ma/Mo 69.5 ± 4.7 52.7 ± 26.3 0.332
CD8+ T cells 10.9 ± 10.0 17.6 ± 15.4 0.533
CD8-CD4- T cells 7.1 ± 1.1 14.7 ± 9.0 0.210
Immature DC 4.6 ± 3.1 3.7 ± 1.6 0.586
Neutrophils 1.6 ± 2.1 4.5 ± 6.7 0.498
Cycling cells 2.2 ± 0.5 1.8 ± 0.7 0.456
B cells 1.5 ± 0.6 2.1 ± 1.4 0.557
Mature DC 0.4 ± 0.1 2.1 ± 1.0 0.041
Epithelial cells 1.0 ± 0.6 0.6 ± 0.2 0.160
Mast cells 1.2 ± 1.8 0.3 ± 0.3 0.270Relative cell proportion were compared between healthy West Highland white terriers
(WHWTs) and WHWTs affected with canine idiopathic pulmonary fibrosis (CIPF) using t-
tests after verification of the distribution normality using Shapiro-Wilk tests. Data are
expressed in mean percentage ± standard deviation.TABLE 4 | Relative cells repartition between healthy and CIPF WHWTs in each
Ma/Mo cluster.
Healthy WHWTs CIPF WHWTs P-value
M0 73.6 ± 4.1 67.2 ±10.0 0.342
M1 18.8 ± 4.1 14.2 ± 6.6 0.329
M2 2.9 ± 0.2 13.5 ± 4.7 0.009
M3 3.2 ±1.1 4.4 ± 1.8 0.356
M4 1.4 ± 1.0 0.7 ± 0.4 0.185December 2020 | Volume 11 | ArticleRelative cell proportion in each macrophages/monocytes (Ma/Mo) cluster were compared
between healthy West Highland white terriers (WHWTs) and WHWTs affected with canine
idiopathic pulmonary fibrosis (CIPF) using t-tests after verification of the distribution
normality using Shapiro-Wilk tests. Data are expressed in mean percentage ± standard
deviation.611749
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(FDR q-value = 0.007 and 0.002) (Figures 4A, B). Differentially
overexpressed genes identified in relation with pulmonary fibrosis
included SFTPC (encoding surfactant protein C), CCL5 (encoding
C-C motif chemokine ligand 5), FN1 (encoding fibronectin 1),
CXCL8 (encoding C-X-C motif chemokine ligand 8), ATP11A
(encoding ATPase phospholipid transporting 11A) and SPP1
(encoding osteopontin) in cluster M1 and CCL2 (encoding C-C
motif chemokine ligand 2), SPP1, FN1, CCL3 (encoding C-Cmotif
chemokine ligand 3), TIMP1 (encoding metallopeptidase inhibitor
1), IL1RN (encoding interleukin 1 receptor antagonist), CXCL8
and CCL4 (encoding C-Cmotif chemokine ligand 4) in cluster M2
(Figure 4C). M0 cells were negatively enriched for pulmonary
fibrosis with a NES of −2.04 (FDR q-value = 0.002). The other
clusters were not significantly associated with pulmonary fibrosis
processes (FDR q-value = 0.145 and 0.289 for cells of cluster M3
and M4, respectively).
Comparison Between Animal Status
Differential gene expression between cells from healthy
WHWTs and WHWTs affected with CIPF in each Ma/Mo
cluster was also assessed (Supplementary Table 6) and was
essentially found for cells in cluster M1. DEGs in cluster M1Frontiers in Immunology | www.frontiersin.org 7between CIPF and healthy WHWTs were mapped to the
Comparative Toxicogenomics Database Pulmonary fibrosis
gene set to assess pulmonary fibrosis signatures. NES in
pulmonary fibrosis processes was at 2.01 (FDR q-value =
0.008) (Figure 5A). Genes involved in pulmonary fibrosis
processes found to be upregulated in CIPF compared with
healthy WHWTs in cluster M1 included FN1, SPP1, CXCL8,
and PLAU (encoding plasminogen activator urokinase)
(Figures 5D–G). The differential expression between healthy
and CIPF WHWTs of those molecules in all Ma/Mo clusters is
illustrated in Supplementary Figure 2. Moreover, in cluster
M1, enrichment analysis with Hallmark gene sets indicated that
cells from CIPF WHWTs were enriched for processes known to
be associated with fibrosis including “epithelial mesenchymal
transition (EMT)” (Figure 5B) and “angiogenesis” (Figure 5C)
(NES of 1.86 and 1.88; FDR q-value = 0.039 and 0.068,
respectively). Genes associated with these two gene sets and
overexpressed in CIPF dogs included VIM (encoding
vimentin), FN1, SPP1, THY1 (encoding Thy-1 cell surface
antigen, CD90) for “EMT” gene set and SPP1, VCAN
(encoding large fibroblast proteoglycan) and S100A4
(encoding S100 ca lc ium bind ing prote in A4) for
“angiogenesis” gene set (Supplementary Table 6).FIGURE 3 | Differential genes expression analysis between macrophages/monocytes (Ma/Mo) clusters. Dot plot showing the expression of the principal gene
markers used to characterize each Ma/Mo cluster. Dot size represents the percentage of cells expressing the genes, while the dot color represents the average
expression of the indicated genes.December 2020 | Volume 11 | Article 611749
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In this study, we analyzed Ma/Mo clusters in the BALF from
healthy WHWTs compared with WHWTs affected with CIPF.
Five Ma/Mo clusters were identified. Among them, we described
a cluster of monocytes present in larger proportion in CIPF
WHWTs than in healthy WHWTs. Expression of cells in this
cluster was enriched for pulmonary fibrosis processes and eight
genes associated with fibrosis were overexpressed in this cluster
including CCL2, SPP1, FN1, CCL3, TIMP1, IL1RN, CXCL8, and
CCL4. We also identified a cluster of monocyte-derived
macrophages enriched for inflammatory and pulmonary
fibrosis processes in which the gene expression differed
between CIPF and healthy WHWTs with an enrichment forFrontiers in Immunology | www.frontiersin.org 8pulmonary fibrosis but also EMT and angiogenesis processes.
We identified four overexpressed genes associated with
pulmonary fibrosis processes in CIPF compared with healthy
dogs in this cluster including FN1, SPP1, CXCL8, and PLAU.
In this study, similar cell populations and clusters were
identified compared with previously published data on scRNA-
seq analysis in BALFs from healthy dogs and included Ma/Mo, T
cells either CD8+ or CD8−CD4−, DCs either mature or immature,
neutrophils, B cells, epithelial cells, mast cells, and cycling cells (18).
We were not able to differentiate between ciliated and non-ciliated
epithelial cells which can be due to either the low proportion or the
absence of ciliated epithelial cells in our samples (37) as rare cell
populations may be missed using scRNA-seq (15). As already
reported (18), eosinophils were not identified using scRNA-seq,FIGURE 4 | Enrichment in pulmonary fibrosis processes in M1 and M2 macrophages/monocytes clusters compared to others. (A, B) Gene set enrichment analyses
between Comparative Toxicogenomics Database Pulmonary Fibrosis gene set and differentially expressed genes in M1 and M2 clusters, respectively, compared to
others. (C) Dot plot showing the expression of genes involved in pulmonary fibrosis processes found to be upregulated in cluster M1 and M2 compared to others.
Dot size represents the percentage of cells expressing the genes, while the dot color represents the average expression of the indicated genes.December 2020 | Volume 11 | Article 611749
Fastrès et al. Pro-Fibrotic Macrophages in CIPF WHWTsprobably secondary to their RNase content conducting to the
degradation of mRNAs in those cells (38).
In healthy conditions, lung macrophages are known to be
extremely heterogeneous and play a crucial role in the regulation
of the homeostasis of the lung. In addition to their immune
defense function, they also exerted an indispensable role in organ
development, maintenance of homeostasis and repair (3, 17). In
the lung, the majority of the macrophages are AMs which are
resident and self-renewing macrophages (3). They have been
identified in this study by their expression of MARCO and
corresponded to cells of cluster M0 and M3 (3, 18, 26). In
inflammatory conditions, the lung is rapidly infiltrated by
recruited monocytes which gradually differentiate into
monocyte-derived macrophages and then AMs (3). Here, we
observed a higher proportion of monocytes (cells from cluster
M2) in CIPF dogs that are probably recruited secondary to lungFrontiers in Immunology | www.frontiersin.org 9fibrosis in higher proportion than in healthy dogs. This increased
number of macrophages and myeloid cells was also reported as
an early event in bleomycin-induced lung fibrosis mouse model
(6). As M2 cluster cells were enriched in pulmonary fibrosis
processes, we suggest that their increased proportion in CIPF
condition could participate to the onset and/or to the
perpetuation of the fibrosis process in WHWTs.
The Ma/Mo involved in pro-fibrotic processes in this study
can be considered as immature macrophages as they were
identified as either monocyte-derived macrophages (cluster
M1) or monocytes (cluster M2). Recently, transcriptomic
profiling of macrophages collected over the time course of
bleomycin induced fibrosis showed that during monocyte
maturation, genes linked to fibrosis are most highly expressed
during their differentiation and progressively downregulated
with the maturation of the cells into AMs (39). This is in lineFIGURE 5 | M1 macrophages/monocytes cluster enrichment in pulmonary fibrosis processes in CIPF compared with healthy dogs. (A–C) Gene set enrichment
analyses in M1 cluster between differentially expressed genes in West Highland white terriers (WHWTs) affected with canine idiopathic pulmonary fibrosis (CIPF)
compared to healthy WHWTs and the Comparative Toxicogenomics Database Pulmonary fibrosis gene set and epithelial mesenchymal transition and angiogenesis
Hallmark gene sets. (D–G) T-distributed stochastic neighbor embedding (t-SNE) plot of cluster M1 cells showing overexpressed genes in CIPF compared with
healthy WHWTs, associated with pulmonary fibrosis according to the Comparative Toxicogenomics Database Pulmonary fibrosis gene set. Color represents the
average expression of the indicated genes.December 2020 | Volume 11 | Article 611749
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recruited macrophages (clusters M1 and M2) have greater
fibrotic capacity than mature AMs (clusters M0 and M3).
Targeting those particularly pro-fibrotic recruited immature
macrophage clusters could be a potential novel strategy for the
prevention and the therapy of CIPF.
DEGs between healthy and CIPF WHWTs were essentially
found in the M1 cluster. Moreover, M1 cells in CIPF dogs were
enriched for EMT, angiogenesis and pulmonary fibrosis
processes. EMT is considered as one of the phenomena by
which collagen-producing fibroblasts and myofibroblasts
accumulate, creating a pro-fibrotic environment (40). Indeed,
epithelial cells differentiate to acquire features of mesenchymal
cells including invasion, migration, and production of
extracellular matrix (40). Altered EMT process is the most
widely accepted pathogenetic mechanism in IPF patient (40)
and could also participate in the development of CIPF as
suggested by this study. Angiogenesis is another well-known
mechanism involved in IPF, which is targeted by Nintedanib, an
anti-angiogenesis molecule used in human for its properties
against the vascular endothelial growth factor (VEGF) pathway
(41). Involvement of angiogenesis in CIPF has only been assessed
through the measurement of VEGF concentration in serum
without results (42). To the authors’ best knowledge, none of
the molecules identified in the present study and linked to
angiogenesis has been studied in CIPF.
Among genes found to be associated with pulmonary fibrosis
processes, only CCL2 and CXCL8 have already been associated
with CIPF (2). Indeed, it has been shown that mRNA expression
of CXCL8 and CCL2 was increased in CIPF lungs compared with
controls (2). Moreover, CCL2 and CXCL8 chemokine
concentrations were increased in CIPF WHWTs compared
with healthy WHWTs in both serum and BALF and only in
BALF respectively (2). The osteopontin (SPP1 gene) is a
glycoprotein secreted by numerous cell types including
macrophages which has been proved to be closely related to
IPF (7, 43–46). Indeed, high level of expression and increased
BALF protein concentration have been reported in IPF mouse
models but also in IPF patients (45). Such findings suggest that
osteopontin could be used as a potential biomarker and a
therapeutic target for treating fibrotic lung diseases (43). The
fibronectin 1 (FN1 gene) is a mediator of cell matrix adhesions. It
promotes myofibroblast differentiation and is found in
abundance in the lungs of IPF patients (47). CCL3 and
CCL4, also known as macrophage inflammatory protein 1-
alpha and beta, are chemoattractant cytokines (48–50)
suspected to play a role in sustaining inflammation and the
chronic course of IPF by recruiting inflammatory cells such as
neutrophils (49–51). Their expression in CIPF dogs could be
related to the higher rate of neutrophils found in the BALF of
CIPF compared to healthy dogs. The tissue inhibitor of
metalloproteinase (TIMP-1 gene) probably contributes,
through its control of matrix metalloproteinase catalytic1 https://support.10xgenomics.com/single-cell-gene-expression/software/
pipelines/latest/troubleshooting#alerts (accessed March 16, 2020).
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microenvironment in IPF patient as well as in IPF mouse
model (52, 53). It has also a potential value as biomarker in
patients with IPF (54). The interleukin-1 receptor antagonist
(encoding IL-1RA) is a cytokine produced by alternatively
activated AMs. The protein level was increased in IPF patients
compared with healthy volunteers (55, 56) and in patients with
acute exacerbation of IPF compared with stable IPF patients
suggesting that this protein could be of interest as diagnostic and
prognostic marker (56). The role of the plasminogen activator
urokinase (PLAU gene) in pulmonary fibrosis is not clear. The
protein level has been showed to be low in BALF of IPF patient
(57, 58) and the molecule was showed to be protective against
fibrosis development in IPF mouse model (59). Recently, the
protective role of the plasminogen activator was controverted as
its presence was associated with increased plasmin formation
which in turn activates structural and inflammatory cells driven
fibrosis (57). PLAU overexpression in this study indicates that
fibrinolytic processes are present in CIPF dogs. Whether it is
protective or not remains unclear. Further studies are needed to
better assess the potential role of all these molecules in CIPF
pathogenesis and their utility as biomarkers of disease
progression and as potential therapeutic target.
The present study had some limitations. First, the analysis of
scRNA-seq data remains limited by the poor annotation of
canine genomic dataset highlighting the need for further
studies to optimize the use of this technique in healthy and
diseased dogs. Indeed, the percentage of reads mapped
confidently to the transcriptome had to be from at least 30%1,
which is not the case in this study. Secondly, our study involved a
relatively low number of dogs either healthy or affected with
CIPF. Indeed, even if the transcriptomic profiling costs are
falling, the use of the scRNA-seq remains currently quite
expensive. However, even with this small number of subjects
and with the lack of annotation of the canine genome, we were
able to identify the different cell populations, their genes
expression and their DEGs in CIPF condition. We were also
able to detect the genes already identified as involved in CIPF
such as CXCL8 and CCL2. Finally, it should be noted that in
some Ma/Mo clusters, DEGs included markers normally
expressed by other cell types, mainly in M4 cluster which
expressed Ma/Mo and T cells markers. This likely results from
contamination from ambient RNA released during BALF
processing. This contamination is a known limitation that can
occur in scRNA-seq experiments (60, 61). Another explanation
would be that these cells are in fact doublets. Doublets are a
known confounding factor in scRNA-seq analysis (62) that can
be reduced by decreasing cell number introduced in the
ChromiumTM Controller (63) and by filtering out cells with a
really high gene count (62) as it was done in this study.CONCLUSION
Using scRNA-seq in BALF specimens from healthy WHWTs
and WHWTs affected with CIPF, we were able to reveal the
presence of pro-fibrotic monocytes, more abundant in CIPF thanDecember 2020 | Volume 11 | Article 611749
Fastrès et al. Pro-Fibrotic Macrophages in CIPF WHWTsin healthy WHWTs, reflecting the inflammation that occurs in
fibrotic lung. The presence of those monocytes enriched with
pro-fibrotic genes probably participates to the onset and/or the
perpetuation of CIPF in WHWTs. Moreover, monocyte-derived
macrophages enriched in pro-fibrotic genes in CIPF compared
with healthy WHWTs were also identified. This cluster was also
enriched with EMT and angiogenesis processes, which are
known to play an important role in IPF.
The results of that study offer promise for the better
understanding of the role of macrophages in CIPF pathogenesis
and the identification of new biomarkers and therapeutic targets to
better diagnose, follow and treat the disease.DATA AVAILABILITY STATEMENT
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